H J Lee, K Han, H Soh, S-J Koh, J P Im, J S Kim, H E Park, M Kim
Issues - Maggio 2022
H J Lee, K Han, H Soh, S-J Koh, J P Im, J S Kim, H E Park, M Kim
K Papp, C Paul, C E Kleyn, Y-H Huang, T-F Tsai, C Schuster, C El Baou, A Toth, E Riedl, U Mrowietz
Time to loss of response following withdrawal of ixekizumab in patients with moderate-to-severe psoriasis
Acta Derm Venereol. 2022 Mar 15;102:adv00672A Blauvelt, N Shi, M Murage, T Ridenour, C Lew, N Somani, B Zhu, N Zimmerman, S Kern, R Burge
Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: A real-world study
J Drugs Dermatol. 2022 Apr 1;21(4):399-407A Blauvelt, T-F Tsai, R G Langley, M Miller, Y-K Shen, Y Y, Y-W Yang, K A Papp, L Puig
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
J Am Acad Dermatol. 2022 Apr;86(4):827-834C Ryan, L Guenther, P Foley, J Weisman, R T Burge, G Gallo, K See, M McKean-Matthews, C C Bertram, J F Merola
Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e277-e279J F Merola, H Tian, D Patil, C Richardson, A Scott, Y-H Chen, N Kim, P Hur, A W Armstrong
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States
J Am Acad Dermatol. 2022 Apr;86(4):748-757R Oliver, J G Krueger, S Glatt, P Vajjah, C Mistry, M Page, H Edwards, S Garcet, X Li, B Dizier, A Maroof, M Watling, A El Baghdady, D Baeten, L Ionescu, S Shaw
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study
Br J Dermatol. 2022 Apr;186(4):652-663J Liu, A Thatiparthi, A Martin, J J Wu
Association between psoriasis and thyroid dysfunction among US adults in the 2009-2014 National Health and Nutrition Examination Survey
J Am Acad Dermatol. 2022 Apr;86(4):897-899J J Yang, K A Nguyen, M W Fleischman, O Aly, K Cheng
Psoriasis in liver disease: Associations beyond nonalcoholic fatty liver disease
J Am Acad Dermatol. 2022 Apr;86(4):883-885A Cristaudo, D Graceffa, F Pimpinelli, F Sperati, G Spoletini, C Bonifati, R Pellini, V Lora, M Pontone, O Di Bella, D Bracco, A Morrone
Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e266-e268K Ikumi, K Torii, Y Sagawa, Y Kanayama, A Nakada, H Nishihara, A Morita
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
J Dermatol. 2022 Apr;49(4):e125-e126K A Papp, M J Gooderham, L E Albrecht, M-A Raymond, C W Lynde
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting
Br J Dermatol. 2022 Apr;186(4):726-728John S Barbieri, Rinad S Beidas, George C Gondo, Jessica Fishman, Nathaniel J Williams, April W Armstrong, Alexis R Ogdie, Nehal Mehta, Joel M Gelfand